Minoti Hiremath

517 total citations
22 papers, 405 citations indexed

About

Minoti Hiremath is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Minoti Hiremath has authored 22 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Minoti Hiremath's work include Viral-associated cancers and disorders (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Wnt/β-catenin signaling in development and cancer (6 papers). Minoti Hiremath is often cited by papers focused on Viral-associated cancers and disorders (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Wnt/β-catenin signaling in development and cancer (6 papers). Minoti Hiremath collaborates with scholars based in United States, France and Spain. Minoti Hiremath's co-authors include Pamela Cowin, Sarah Hatsell, Tracey Rowlands, John J. Wysolmerski, Angela Incassati, Pamela Dann, Julie R. Hens, John P. Lydon, Kata Boras-Granic and Lewis A. Chodosh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Minoti Hiremath

18 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minoti Hiremath United States	9	287	219	63	44	30	22	405
Angela Nakauka‐Ddamba United States	8	282 1.0×	169 0.8×	88 1.4×	92 2.1×	26 0.9×	8	429
Marie Kannius‐Janson Sweden	11	288 1.0×	116 0.5×	67 1.1×	70 1.6×	16 0.5×	14	404
Florian Lépinasse France	11	203 0.7×	142 0.6×	22 0.3×	30 0.7×	25 0.8×	12	394
Toranoshin Ayada Japan	8	296 1.0×	127 0.6×	44 0.7×	60 1.4×	89 3.0×	11	450
Alessia Centonze Belgium	5	217 0.8×	229 1.0×	26 0.4×	75 1.7×	35 1.2×	7	338
Janet Lau United States	8	556 1.9×	219 1.0×	196 3.1×	49 1.1×	21 0.7×	9	723
Dorothée Michaux France	8	226 0.8×	107 0.5×	110 1.7×	46 1.0×	12 0.4×	8	358
Gunda Schwaninger Austria	4	347 1.2×	286 1.3×	50 0.8×	128 2.9×	20 0.7×	7	472
Barbara Dessars Belgium	9	159 0.6×	124 0.6×	43 0.7×	89 2.0×	26 0.9×	14	328
Zhaodi Gu Japan	10	338 1.2×	103 0.5×	44 0.7×	86 2.0×	39 1.3×	18	395

Countries citing papers authored by Minoti Hiremath

Since Specialization

Citations

This map shows the geographic impact of Minoti Hiremath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minoti Hiremath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minoti Hiremath more than expected).

Fields of papers citing papers by Minoti Hiremath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minoti Hiremath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minoti Hiremath. The network helps show where Minoti Hiremath may publish in the future.

Co-authorship network of co-authors of Minoti Hiremath

This figure shows the co-authorship network connecting the top 25 collaborators of Minoti Hiremath. A scholar is included among the top collaborators of Minoti Hiremath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minoti Hiremath. Minoti Hiremath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Punekar, Salman R., Jia Luo, S-H.I. Ou, et al.. (2025). 6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 20(3). S10–S11. 1 indexed citations

Worel, Nina, Josè Antonio Pérez-Simón, Pere Barba, et al.. (2020). 29P ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy. Annals of Oncology. 31. S1426–S1427.

Aftab, Blake T., Rhine R. Shen, Norma Guzmán‐Becerra, et al.. (2020). Correlation of Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel with response and survival in rituximab relapsing or refractory EBV+ post-transplant lymphoproliferative disease (PTLD).. Journal of Clinical Oncology. 38(5_suppl). 38–38. 1 indexed citations

Prockop, Susan E., Ran Reshef, Donald E. Tsai, et al.. (2020). Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program Study. Biology of Blood and Marrow Transplantation. 26(3). S61–S62. 2 indexed citations

Prockop, Susan E., Minoti Hiremath, Wei Ye, et al.. (2020). A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Biology of Blood and Marrow Transplantation. 26(3). S274–S274.

Aftab, Blake T., Daniel J. Munson, Philippe Foubert, et al.. (2019). Correlation of circulating EBV-targeted cytotoxic T lymphocyte precursors (EBV-CTLp) and clinical response following tabelecleucel (tab-cel) infusion in patients with EBV-driven disease.. Journal of Clinical Oncology. 37(15_suppl). 2532–2532.

Prockop, Susan E., Ran Reshef, Donald E. Tsai, et al.. (2019). Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program. Blood. 134(Supplement_1). 4071–4071. 5 indexed citations

Prockop, Susan E., Minoti Hiremath, Wei Ye, et al.. (2019). A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV+PTLD) after Failure of Rituximab or Rituximab and Chemotherapy. Blood. 134(Supplement_1). 5326–5326.

Fowler, Nathan, Morton Coleman, Don A. Stevens, et al.. (2018). Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).. Journal of Clinical Oncology. 36(15_suppl). 7549–7549. 15 indexed citations

10.

Hiremath, Minoti, et al.. (2014). CoVE. Scholar Works (Boise State University). 135. 9–18. 1 indexed citations

11.

Hiremath, Minoti & John J. Wysolmerski. (2014). Role of PTHrP in Mammary Gland Development and Breast Cancer. Clinical Reviews in Bone and Mineral Metabolism. 12(3). 178–189. 5 indexed citations

12.

Hiremath, Minoti & John J. Wysolmerski. (2013). Parathyroid Hormone-Related Protein Specifies the Mammary Mesenchyme and Regulates Embryonic Mammary Development. Journal of Mammary Gland Biology and Neoplasia. 18(2). 171–177. 39 indexed citations

13.

Hiremath, Minoti, Pamela Dann, Jennifer Fischer, et al.. (2012). Parathyroid hormone-related protein activates Wnt signaling to specify the embryonic mammary mesenchyme. Development. 139(22). 4239–4249. 29 indexed citations

14.

Boras-Granic, Kata, Joshua VanHouten, Minoti Hiremath, & John J. Wysolmerski. (2011). Parathyroid Hormone-Related Protein Is Not Required for Normal Ductal or Alveolar Development in the Post-Natal Mammary Gland. PLoS ONE. 6(11). e27278–e27278. 11 indexed citations

15.

Mukherjee, Atish, Selma M. Soyal, Jie Li, et al.. (2010). A mouse transgenic approach to induce β-catenin signaling in a temporally controlled manner. Transgenic Research. 20(4). 827–840. 10 indexed citations

16.

Incassati, Angela, et al.. (2009). MMTV-Wnt1 and -ΔN89β-Catenin Induce Canonical Signaling in Distinct Progenitors and Differentially Activate Hedgehog Signaling within Mammary Tumors. PLoS ONE. 4(2). e4537–e4537. 56 indexed citations

17.

Hens, Julie R., et al.. (2009). Analysis of gene expression in PTHrP^−/− mammary buds supports a role for BMP signaling and MMP2 in the initiation of ductal morphogenesis. Developmental Dynamics. 238(11). 2713–2724. 25 indexed citations

18.

Incassati, Angela, et al.. (2009). Correction: MMTV-Wnt1 and -ΔN89β-Catenin Induce Canonical Signaling in Distinct Progenitors and Differentially Activate Hedgehog Signaling within Mammary Tumors. PLoS ONE. 4(3). 8 indexed citations

19.

Hiremath, Minoti, John P. Lydon, & Pamela Cowin. (2007). The pattern of β-catenin responsiveness within the mammary gland is regulated by progesterone receptor. Development. 134(20). 3703–3712. 16 indexed citations

20.

Hatsell, Sarah, Tracey Rowlands, Minoti Hiremath, & Pamela Cowin. (2003). β-Catenin and Tcfs in Mammary Development and Cancer. Journal of Mammary Gland Biology and Neoplasia. 8(2). 145–158. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact